Sawgrass Asset Management LLC trimmed its position in Eli Lilly and Company (NYSE:LLY) by 19.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,500 shares of the company’s stock after selling 1,065 shares during the quarter. Sawgrass Asset Management LLC’s holdings in Eli Lilly and were worth $370,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the company. Pathstone Family Office LLC grew its stake in shares of Eli Lilly and by 100.0% in the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after buying an additional 29 shares in the last quarter. Vantage Financial Partners Ltd. Inc. acquired a new stake in shares of Eli Lilly and in the second quarter valued at about $494,000. Acrospire Investment Management LLC grew its stake in shares of Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after buying an additional 200 shares in the last quarter. Point72 Asia Hong Kong Ltd grew its stake in shares of Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares in the last quarter. Finally, Shine Investment Advisory Services Inc. acquired a new stake in shares of Eli Lilly and in the second quarter valued at about $148,000. Institutional investors own 75.48% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Sawgrass Asset Management LLC Cuts Stake in Eli Lilly and Company (LLY)” was first published by Stock Observer and is owned by of Stock Observer. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thestockobserver.com/2017/11/14/sawgrass-asset-management-llc-cuts-stake-in-eli-lilly-and-company-lly.html.
A number of equities research analysts have recently issued reports on the company. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, October 24th. Barclays PLC increased their target price on Eli Lilly and from $90.00 to $98.00 and gave the company an “overweight” rating in a research note on Friday, October 13th. Berenberg Bank reiterated a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a research note on Thursday, October 26th. Zacks Investment Research lowered Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Cowen and Company reiterated a “buy” rating and issued a $95.00 target price on shares of Eli Lilly and in a research note on Wednesday, October 4th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Hold” and a consensus price target of $89.76.
In related news, major shareholder Lilly Endowment Inc sold 190,000 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $82.53, for a total value of $15,680,700.00. Following the sale, the insider now owns 123,682,287 shares of the company’s stock, valued at approximately $10,207,499,146.11. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. In the last three months, insiders sold 772,003 shares of company stock worth $64,837,441. Company insiders own 0.20% of the company’s stock.
Eli Lilly and Company (LLY) opened at $82.86 on Tuesday. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $89.09. The company has a market capitalization of $91,710.21, a P/E ratio of 20.36, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter last year, the business posted $0.88 EPS. Eli Lilly and’s quarterly revenue was up 9.0% compared to the same quarter last year. sell-side analysts expect that Eli Lilly and Company will post 4.22 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.51%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.